<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02050984</url>
  </required_header>
  <id_info>
    <org_study_id>BASBP</org_study_id>
    <secondary_id>2012CB517805</secondary_id>
    <nct_id>NCT02050984</nct_id>
  </id_info>
  <brief_title>Effect of Bariatric Surgery on Blood Pressure</brief_title>
  <acronym>BASBP</acronym>
  <official_title>A Prospective Study on the Effects of Bariatric Surgery on Blood Pressure in Patients With Obesity and Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiming Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery is generally recommended for obese people with a body mass index (BMI) of&#xD;
      at least 40kg/m2, and for people with BMI 35 kg/m2 and serious coexisting medical conditions&#xD;
      such as diabetes. A variety of studies showed that it cause significant weight loss, recovery&#xD;
      from diabetes and improvement in cardiovascular risk factors, such as blood pressure. The&#xD;
      recent guidelines suggest that patients with a BMI of more than 30 kg/m2 with co morbidities&#xD;
      is a candidate for bariatric surgery. However, the patients with diabetes in Chinese has&#xD;
      lower BMI than that in west country. Therefore, this research is designed to observe whether&#xD;
      bariatric surgery reduce blood pressure in patients with diabetes and relatively lower BMI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of hypertension medication prescription</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of hypertension medication prescription related to the baseline hypertension treatment at 12 months after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of hypertension medication prescription</measure>
    <time_frame>1 month to 6 months</time_frame>
    <description>Reduction of hypertension medication prescription compared to the baseline hypertension treatment at 1, 3 and 6 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in systolic blood pressure</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in diastolic blood pressure</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in body mass index</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in waist circumference</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in body fat distribution</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in fasting plasma insulin</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>3 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in total cholesterol</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in LDL-cholesterol</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in HDL-cholesterol</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in triglycerides</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in artery vasodilative function</measure>
    <time_frame>1 to 12 months</time_frame>
    <description>Endothelium-dependent nitroglycerin(NTG)-induced dilatation and flow-mediated dilatation (FMD) by non-invasive high-resolution ultrasound.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in serum amino acids level</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in sense of taste</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in hepatic enzymes</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in serum creatine</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in serum electrolyte</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in complete blood count</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 to 12 months</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with obesity and diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged between 18 and 60 years old.&#xD;
&#xD;
          -  Type 2 Diabetes diagnosis defined according to WHO 2006 guideline.&#xD;
&#xD;
          -  Body mass index between 25.0 and 39.9 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension â‰¥ 180/120 mmHg;&#xD;
&#xD;
          -  Type 1 diabetes, other types of diabetes or gestational diabetes;&#xD;
&#xD;
          -  Acute complications of diabetes;&#xD;
&#xD;
          -  Cerebrovascular diseases in the last 6 months.&#xD;
&#xD;
          -  Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last 6&#xD;
             months.&#xD;
&#xD;
          -  Baseline psychiatric disorders: schizophrenia, bipolar disorder, severe depression,&#xD;
             psychosis.&#xD;
&#xD;
          -  Renal diseases: diabetic nephropathy, creatinine clearance &lt; 30 ml/min.&#xD;
&#xD;
          -  Advanced peripheral arterial disease&#xD;
&#xD;
          -  Atrophic gastritis&#xD;
&#xD;
          -  Alcoholism or use of illicit drugs&#xD;
&#xD;
          -  Previous laparotomy&#xD;
&#xD;
          -  Severe hepatic disorders&#xD;
&#xD;
          -  Pregnancy or women not using effective contraceptive methods.&#xD;
&#xD;
          -  Recent neoplasm (&lt; 5 years)&#xD;
&#xD;
          -  Immunosuppressant drugs&#xD;
&#xD;
          -  Unable to understanding and follow the study protocol orientations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongbo He, MD.</last_name>
    <phone>86-23-69757880</phone>
    <email>cqhehongbo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiming Zhu, MD., PhD.</last_name>
    <phone>86-23-68767881</phone>
    <email>zhuzm@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongbo He, MD.</last_name>
      <phone>86-23-68757880</phone>
      <email>cqhehongbo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zhiming Zhu, MD.,PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 25, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhiming Zhu</investigator_full_name>
    <investigator_title>Director of the Dept. of Hypertension &amp; Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

